Applied Symbiotic Intelligence
Your next breakthrough is already published. No one has connected the dots.
We produce original scientific intelligence from your published research — evidence-based hypotheses authenticated by domain experts, every claim traced to source, delivered in days, not months.
Validated outcomes

Three numbers from delivered engagements. Every claim traced to source.

>$20M
Potential cost-avoidance identified per engagement
36 hrs
From single paper to publication-ready direction
66 wks → 14 days
Delivery vs incumbent systematic review
The problem

The answers to your hardest scientific questions already exist — scattered across journals, disciplines, and species boundaries that no single researcher reads together. A gene editing lab publishes findings that the immunotherapy team across the hall would recognize as transformative. Two of your own published papers contain a contradiction with millions of dollars in implications. Nobody sees it because nobody holds all the pieces at once.

This fragmentation has a price. Failed trials that published data could have predicted. Research directions that dead-end years later. And discoveries that sit dormant — not because the science failed, but because it never found the right context.

$7.7B
Terminated assets / yr
66 wks
Avg. lit review
50%
Preclinical replication failure
$236B
Patent cliff risk
What changes when you work with us
Research Institutions
Your labs publish extraordinary science — but separate pipelines mean connections go unseen. We surface cross-lab synergies, hidden contradictions, and platform opportunities hiding between your own papers.
$8–23M cost-avoidance identified · 14 days
Pharma, Biotech & Med-Tech R&D
We synthesize across domains — immunology, pharmacology, tumor biology, clinical oncology, device commercialization — and surface interactions your trial designs and IP positioning may not account for. Companion diagnostic white space. Testable predictions from existing tissue.
10+ testable predictions, half requiring no new patients · 2–4 weeks
Clinical & Translational
Published pharmacology data contains corrections that could redirect your program — receptor-level inversions, temporal factors that flip risk-benefit profiles, stratification signals in existing datasets.
Seed paper to 8 intervention protocols · 48 hours
Domain experts as arbiters of truth

AI technologists can evaluate architecture. Only specialists with decades of field experience can judge whether a finding is biologically plausible, methodologically sound, and clinically meaningful. The validations below come from the people whose lifetime work positions them to authenticate the work — not us claiming, them confirming.

Dean of Pharmacy, Major Research University
Reviewed our analysis of a single paper of hers. With zero prior domain exposure, our methodology produced in 36 hours the scientific directions her lab had been pursuing in unpublished research for six years.
36 hours to match 6 years of unpublished lab direction
Oncologist at a major cancer research university
Reviewed our analysis of her own seven-year-old published research — the person on Earth best positioned to judge accuracy.
37 min to first response → co-author in 48 hrs → university publication pipeline in 3 days
Dean of Veterinary Medicine
Reviewed cross-species findings. Championed the work across disciplines and connected us to collaborators at multiple institutions.
Work propagated across institutions on the reviewer’s initiative
Venture Capital — AI for Good
Evaluates hundreds of AI companies for transformative social impact. Compared the work to Palantir twice unprompted. Brokered introductions to a major research institution in the same conversation.
“I have not seen that out there.”
Methodology track record
0
Findings with provenance
12+
Scientific domains engaged
0
Patent-pending filings
0
Institutions where experts validated the work
In 36 hours, from a single published paper she had written, our methodology arrived at the scientific directions her laboratory had been pursuing for six years in unpublished research.
Single-paper analysis · Dean of pharmacy at a major research university · April 2026
Why nobody else does this
Billions of dollars have been spent building AI molecules. No AI-discovered drug has reached Phase 3. Those companies built answers. We sell the questions — and the questions are worth more.

Everyone has AI. AI is infrastructure, like electricity. What ASI does is not “use AI better.” We operate upstream — at the level of what to ask, how to verify, and when to trust the answer. The methodology is the product. The intelligence speaks for itself. That upstream position is also why operators, advisors, and partners with their own client lanes find a fit — the methodology layers under existing commercialization, M&A, and academic-IP work.

Four independent competitive analyses found no company selling what we sell — packaged novel scientific hypotheses with evidence provenance at consulting-tier pricing. The space appears vacant.

Our system does not generate facts. It generates evidence-based hypotheses that domain experts authenticate — the symbiosis between methodology and field expertise is the architecture. Applied Symbiotic Intelligence is the name because the symbiosis is the mechanism.

Our methodology stress-tests its own conclusions before delivery. Every claim is adversarially challenged inside the pipeline — errors caught, overclaims corrected, scope limitations documented. We deliver hypotheses with their stress-tests attached.
How to start
1
Discovery Pilot We analyze a small set of your published papers and show you what we find. If the intelligence is valuable, we discuss a full engagement. You see the quality before any commitment. Structured briefing with findings, evidence chains, and identified opportunities · 1–2 weeks Engagements begin at five figures
2
Intelligence Product A comprehensive cross-domain analysis on a therapeutic area, pipeline asset, or strategic question of your choosing. Dozens to hundreds of papers synthesized into actionable cross-paper connections, testable predictions, and cost-avoidance quantified to your program’s economics. Full intelligence package — findings, evidence provenance, testable hypotheses, strategic implications · 2–4 weeks
3
Intelligence Partnership Ongoing cross-domain sight across your portfolio. Continuous intelligence as your programs evolve, new papers publish, and the competitive landscape shifts. Our methodology compounds — each engagement builds on everything before it. Recurring intelligence briefings, priority analysis of new publications, direct analytical access
Who we are

Three co-founders. Zero external funding. A methodology that emerged through years of first-principles convergence — lived experience that cannot be reverse-engineered from the outputs alone. Seven patent-pending applications documenting the architecture. Domain experts at multiple institutions have authenticated the work as something they have not seen elsewhere.

Ryan Gruzen
Co-Founder & CEO
Cross-domain intelligence production and client relationships. Founded Pet Portal AI (Plug and Play Accelerator). Leads all analytical operations and scientific synthesis.
LinkedIn →
Harold Lee
Co-Founder & CTO
Technical architecture and AI systems. MBA. U.S. patent holder. Former CEO of Music Prodigy (reached #1 in 20 countries). Builds the infrastructure that powers our methodology.
LinkedIn →
Devin Pellegrino
Co-Founder & Chief Architect
Devin designed the knowledge architecture that makes cross-domain connections possible. Background in neuroscience, mechanical engineering, and systems design, Georgia Tech.
LinkedIn →

Your published papers already contain breakthroughs nobody has connected.

We find them. Every finding traced to its source. Every hypothesis stress-tested before you see it. Engagements begin with a scoped Discovery Pilot — structured, priced, and delivered in 1–2 weeks.

Patent-pending methodology · Every claim traced to source · Domain-expert authenticated